Investors

Corporate Profile
We are a clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases.

Leveraging our proprietary ERYCAPS platform, which uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, we have developed a pipeline of product candidates targeting markets with high unmet medical needs. Our initial focus is on the treatment of blood cancers, including acute lymphoblastic leukemia, or ALL, and acute myeloid leukemia, or AML, by depriving tumors of nutrients necessary for their survival, which is referred to as tumor starvation.
Stock Quote
ERYP.PA (Common Stock)
ExchangeParis (Euro)
Price€24.60
Change (%) Stock is Down 0.28 (1.13%)
Volume50,289
Data as of 04/28/17 5:35 p.m. ET
Refresh quote
Recent NewsMore >>
DateTitle  
04-Apr-2017ERYTECH Announces Launch of Investigator-Initiated Phase 2 Study of eryaspase (GRASPA®) for ALL
LYON, France--(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced the launch of an investigator-initiated study to evaluate eryaspase, also known by the trade name GRASPA®, in patients with acute lymphoblastic leukemia (ALL). The study wil... 
 Printer Friendly Version
04-Apr-2017Erytech: Information Related to Total Number of Voting Rights and Shares Composing the Share Capital – March 2017
Article 223-16 of general regulation of French Autorité des Marchés Financiers LYON, France--(BUSINESS WIRE)--Apr. 4, 2017-- Regulatory News: Erytech (Paris:ERYP) (ADR:EYRYY): Date   Total of shares composing the share capital   Total of brut(1) voting ri... 
 Printer Friendly Version
03-Apr-2017ERYTECH Makes Its 2016 Reference Document Available
LYON, France--(BUSINESS WIRE)--Apr. 3, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the clinical-stage biopharmaceutical company developing innovative therapies for rare forms of cancer and orphan diseases based on its proprietary ERYCAPS platform, encapsulating therapeutic drug substances inside red blood cells, today announced that it had filed on March 31, 2017 with the “Autorité des Marchés Fi... 
 Printer Friendly Version
27-Mar-2017ERYTECH Reports Positive Phase 2b Data for eryaspase for the Treatment of Metastatic Pancreatic Cancer
Conference call and webcast on Tuesday, March 28th at 14:30 pm CET/08:30 am EDT Primary progression-free survival (PFS) and overall survival (OS) endpoints met in patients with low asparagine synthetase (ASNS) Statistically significant improvement of OS and PFS in the entire patient population LYON, France--(BUSINESS WIRE)--Mar. 27, 2017-- Regulatory News: ERYTECH Pharma (Paris:ERY... 
 Printer Friendly Version
Upcoming EventsMore >>
DateTitle
05/18/17
First Quarter 2017 Financial Results and Business Update: Press Release: Thursday, May 18, 2017 (after market)
05/19/17 3:00 p.m. CET
First Quarter 2017 Financial Results and Business Update:Conference Call
06/27/17 9:30 a.m. CET
General Meeting of Shareholders
LocationParis, France
Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Erytech Pharma SA posts new information to the site. Just enter your e-mail address and click Submit.
 
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources
Top